DelveInsight's "Invasive Pneumococcal Disease - Market Insights, Epidemiology, and Market Forecasts - 2034" [https://www.delveinsight.com/report-store/invasive-pneumococcal-disease-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr] Provides a comprehensive analysis of invasive pneumococcal disease, including historical and projected epidemiological trends in the United States, five EU countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Key Highlights of the Invasive Pneumococcal Disease Market Report
Significant Market Growth: DelveInsight predicts the IPD market in the 7MM region to grow significantly from 2020 to 2034.
Epidemiological trends:
The incidence of IPD in Spain is estimated to be 15.08 per 100,000 people (95% CI: 11.01 to 20.65), while in Italy it is 2.56 per 100,000 people (95% CI: 1.54 to 4.24).
From 2022 to 2023, IPD incidence increased by 34% in children under 15 years of age, but decreased by 17% in adults (15 years of age and older) compared to 2019 to 2020.
Recent trends in the IPD market:
January 2025: Vaxcyte's VAX-31 (31-valent pneumococcal conjugate vaccine) receives FDA IND clearance for infants to protect both infants and adults from IPD.
June 2024: Merck's CAPVAXIVE (pneumococcal 21-valent conjugate vaccine) receives FDA approval to vaccinate adults 18 years and older against pneumococcus.
New treatments: GSK5101955, GSK5101956, and GBP-410 are currently in development.
Key market players: Pfizer, Merck, Wyeth Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme Corporation, Affinivax/Astellas, Vaxyte, Immunobiology, Eubiologics, etc.
For detailed insights on market trends, drug uptake, treatment scenarios, and epidemiological patterns, Invasive pneumococcal disease market forecast
Overview of Invasive Pneumococcal Disease
Invasive pneumococcal disease (IPD) is a serious bacterial infection caused by Streptococcus pneumoniae that causes serious morbidity and death, especially in young children and the elderly.
Common IPD symptoms:
pneumonia
Acute otitis media (middle ear infection)
Meningitis (brain membrane infection)
Potentially life-threatening bacteremia/sepsis
High risk factors for IPD:
Asplenia or splenic insufficiency
Chronic diseases (respiratory, heart, kidney, liver)
Diabetes requiring insulin/medication
People with a weakened immune system (after transplantation, chemotherapy, etc.)
Epidemiology of invasive pneumococcal disease
This report provides past, current, and projected epidemiological trends in the 7MM countries from 2020 to 2034. Analyze diagnosed patient populations and identify factors influencing epidemiological trends through extensive research and expert opinion.
Classification of epidemiology:
Total incidence of invasive pneumococcal disease
Cases by age
Cases according to gender
Treatable cases
To explore IPD epidemiology drivers, visit: Epidemiology prediction report
Drug uptake and pipeline development for invasive pneumococcal disease
The Drug Adoption section focuses on the adoption rate of newly launched and upcoming treatments in the IPD market. This includes:
Market share and sales performance of new IPD drugs
Comparison of therapeutics for market penetration insights
Pipeline development, including licensing agreements, acquisitions, and mergers
Market strengths and weaknesses
Strengths:
Massive immunization programs (PCVs) have reduced the spread of diseases and increased market stability.
Continuing research and development efforts are improving the next generation of vaccines and antibiotics.
Weaknesses:
The increase in drug-resistant pneumococcal strains limits treatment options.
The high cost of vaccines and treatments hinders access, especially in low-income areas.
Scope of the Invasive Pneumococcal Disease Market Report
Research period: 2020 to 2034
Target region: 7MM (US, EU5, Japan)
Main treatments: GSK5101955, GSK5101956, GBP-410, etc.
Key market players: Pfizer, Merck, Wyeth Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme Corporation, Afinivax/Astellas, Vaxyte, Immunobiology, Eubiologics
Market Dynamics: Drivers, Barriers, Competitive Environment (SWOT, PESTLE, Porter's Five Forces, BCG Matrix)
Analysis of unmet needs and market access
For detailed insights into the key players and advances in the IPD treatment landscape, please visit: Invasive Pneumococcal Disease Market Analysis Report
table of contents
1. Invasive Pneumococcal Disease Market Report Overview
2. Summary of invasive pneumococcal disease
3. SWOT analysis of invasive pneumococcal disease
4. Summary of patient proportion (%) with invasive pneumococcal disease
5. Invasive Pneumococcal Disease Market Overview
6. Invasive pneumococcal disease: Background and overview of the disease
7. Epidemiology and patient population of invasive pneumococcal disease
8. Number of patients with invasive pneumococcal disease by country
9. Current treatments and medical practices for invasive pneumococcal disease
10. Unmet needs in invasive pneumococcal disease
11. New treatments for invasive pneumococcal disease
12. Invasive Pneumococcal Disease Market Outlook
13. Invasive Pneumococcal Disease Market Analysis by Country (2020-2034)
14. Market Access and Reimbursement of Treatments for Invasive Pneumococcal Disease
15. Invasive Pneumococcal Disease Market Drivers
16. Invasive Pneumococcal Disease Market Barriers
17. Invasive Pneumococcal Disease Appendix
18. How to report invasive pneumococcal disease
19. DelveInsight Features
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare business consultant and market research firm specializing in life sciences. We support pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance.
We also provide healthcare consulting services that accelerate business growth with the benefit of market analysis and overcome challenges with a practical approach.
Contact information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
